Large Inflow of Money Witnessed in NuVasive

NuVasive (NUVA) : Thursdays money flow indicated an uptick to downtick ratio was at 1.8. The total value of inflow transactions on upticks was $12.62 million, whereas, the total value of outflow trades on downticks was $7 million. The total money flow was $5.62 million, which shows a mild bullish bias. The total money flow into the stock in block trades was $6.86 million. The total value of the trades done on upticks was $6.86 million. NuVasive (NUVA) was trading with a -0.85% change over previous days close. It fell $0.51 during the day and reached $59.71. The stock was -0.43% compared to the previous weeks close.


NuVasive (NUVA) : Average target price received by NuVasive (NUVA) is $60.55 with an expected standard deviation of $3.75. The most aggressive target on the stock is $68, whereas the most downbeat target is $56. 11 financial analysts are currently covering the stock. The stock has recorded a 20-day Moving Average of 1.72% and the 50-Day Moving Average is 7.06%.

NuVasive (NASDAQ:NUVA): The stock opened at $60.01 on Thursday but the bulls could not build on the opening and the stock topped out at $60.31 for the day. The stock traded down to $59.52 during the day, due to lack of any buying support eventually closed down at $59.71 with a loss of -0.85% for the day. The stock had closed at $60.22 on the previous day. The total traded volume was 688,072 shares.

Nuvasive, Inc. is a global medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its marketed product portfolio is focused on applications for spine fusion surgery. Its product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The MAS platform combines three categories of solutions that collectively minimize soft tissue disruption during spine fusion surgery, provide visualization and are designed to enable reproducible outcomes for the surgeon and the patient. The platform includes the Companys software-driven nerve detection and avoidance systems, including NVM5 and NVJJB, Intra-Operative Monitoring (IOM) services and support; MaXcess, which is an integrated split-blade retractor system, and a variety of implants and biologics.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *